Skip to main content
SINOTHERAPEUTICS INC. logo

SINOTHERAPEUTICS INC. — Investor Relations & Filings

Ticker · 688247 ISIN · CNE100005PL9 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 391 across all filing types
Latest filing 2025-02-26 Earnings Release
Country CN China
Listing Shanghai Stock Exchange 688247

About SINOTHERAPEUTICS INC.

https://www.sinotph.com/en/

Sinotherapeutics Inc. is a pharmaceutical company specializing in the research, development, and commercialization of complex generic drugs and innovative drug delivery systems. The company focuses on high-barrier formulations, particularly oral solid dosage forms with modified-release or controlled-release profiles. Utilizing advanced technology platforms, Sinotherapeutics develops products designed to improve patient compliance and therapeutic outcomes. Its operations encompass the full lifecycle of drug development, from formulation design and clinical evaluation to large-scale manufacturing under global quality standards. The company maintains a robust pipeline targeting various therapeutic areas, including cardiovascular diseases, central nervous system disorders, and metabolic conditions. Sinotherapeutics aims to provide high-quality, affordable medications by leveraging its expertise in complex chemistry and pharmaceutical engineering.

Recent filings

Filing Released Lang Actions
2024年度业绩快报公告
Earnings Release Classification · 95% confidence The document is titled as a "2024年度业绩快报公告" which translates to "2024 Annual Performance Express Report Announcement." It contains preliminary financial data for the year 2024, including revenue, profit, and earnings per share, but explicitly states that the data is preliminary, unaudited, and subject to change in the final audited annual report. The document is relatively short (1831 characters) and serves as a quick earnings update rather than a full annual report. It also includes a risk warning about the preliminary nature of the data and advises investors to refer to the final audited annual report. This type of document is consistent with an Earnings Release (ER), which provides initial key financial highlights for a fiscal period but is not the full audited report itself.
2025-02-26 Chinese
海通证券股份有限公司关于上海宣泰医药科技股份有限公司2025年度日常关联交易预计的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from Haitong Securities regarding the anticipated related party transactions for the year 2025 of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It includes comprehensive data tables on transaction amounts, categories, related parties, and explanations for variances compared to previous years. It also contains detailed descriptions of the related parties, their business scope, financial status, and ownership. The content is focused on compliance with stock exchange listing rules and supervisory guidelines, specifically related to ongoing related party transactions. This type of document is a formal audit or verification report on related party transactions, which fits the category of an Audit Report / Information (AR) rather than a full Annual Report or other categories. The document length (15,000 characters) and detailed financial and procedural content support this classification. There is no indication that this is a mere announcement or a presentation, nor is it a transcript or a regulatory filing of a different nature. Therefore, the best fit is Audit Report / Information (AR).
2025-02-19 Chinese
第二届监事会第十次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement of the resolution from the 10th meeting of the 2nd Supervisory Board of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. It details the meeting attendance, the approval of a proposal regarding the company's expected related party transactions for 2025, and references another announcement for detailed content. The document is short (606 characters) and serves as a meeting resolution announcement rather than a full report or financial statement. It does not contain financial data or detailed management discussion, nor is it a regulatory certification or voting result. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-02-19 Chinese
关于2025年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the expected daily related party transactions for the fiscal year 2025. It details the nature, amounts, counterparties, and pricing policies of these related party transactions. It includes information on the board and independent directors' approvals and opinions, as well as a sponsor institution's verification opinion. The document is a formal disclosure about anticipated related party transactions, which is a regulatory announcement rather than a financial report or management discussion. It does not contain financial statements or detailed financial analysis but focuses on compliance and disclosure of related party dealings. Therefore, it fits best into the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-02-19 Chinese
关于股份回购实施结果的公告
Transaction in Own Shares Classification · 100% confidence The document is an announcement from Shanghai Xuantai Pharmaceutical Technology Co., Ltd. regarding the results of a share repurchase program. It details the approval, implementation, and completion of the share buyback, including the number of shares repurchased, prices, and future plans for the repurchased shares. The document does not contain financial statements or detailed financial analysis but focuses on the share repurchase activity and its compliance with regulations. This fits the definition of a Transaction in Own Shares (POS) filing, which reports on the company's buyback of its own shares.
2025-02-18 Chinese
关于持股5%以上股东权益变动触及1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a change in shareholding by a shareholder holding more than 5% of the company's shares. It details the reduction in shares held by the shareholder, the percentage change, and confirms that this change does not affect control of the company. The document includes specific shareholding percentages before and after the change and references a prior announcement of a share reduction plan. This type of document fits the definition of a Major Shareholding Notification (MRQ), which involves notifications of changes in significant share ownership levels crossing thresholds. The document is not a full financial report, earnings release, or regulatory filing of another type, but a specific notification about shareholding changes.
2025-02-06 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.